Amorcyte Inc.
4 Pearl Court
Suite C
Allendale
New Jersey
07401
United States
Tel: 908-510-0617
Website: http://www.amorcyte.com/
16 articles about Amorcyte Inc.
-
NeoStem, Inc. Subsidiary, Amorcyte Inc., Announces Significant Expansion in Its Claims Granted to Protect the Use of CD34+ Cells
9/10/2012
-
Amorcyte Inc., a NeoStem, Inc. Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction
1/25/2012
-
Amorcyte Inc., a NeoStem, Inc. Company, Announces Expansion of Intellectual Property Coverage
1/10/2012
-
NeoStem, Inc. Closes Amorcyte Inc. Acquisition
10/18/2011
-
NeoStem, Inc. Provides Update on Amorcyte Inc. Clinical Progress and Reports Results for Second Quarter
8/15/2011
-
NeoStem, Inc. Signs Definitive Merger Agreement to Acquire Amorcyte Inc. in Equity Transaction
7/15/2011
-
Amorcyte Inc. Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients
12/21/2010
-
Amorcyte Inc. Granted Landmark Patent
9/13/2010
-
Amorcyte Inc. Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at American College of Cardiology Annual Scientific Session
3/30/2009
-
Amorcyte Inc. Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction
4/1/2008
-
Amorcyte Inc. Cardiac Cell Therapy Trial Completes Second of Four Phases
5/8/2007
-
Amorcyte Inc. Cardiac Cell Therapy Trial Passes First Stage And Opens Two New Sites
1/3/2007
-
Amorcyte Inc. Secures Additional Funding To Expand Clinical Program In Cardiovascular Cell Therapy
10/23/2006
-
Amorcyte Inc. Secures Production Capacity For Lead Cell Therapy Product
6/27/2006
-
Amorcyte Inc. Closes $4.2 Million Series A Financing
6/19/2006
-
Amorcyte Inc. Opens Cell Therapy Trial For Cardiovascular Disease At Emory University
6/12/2006